title: Peroxisome proliferator-activated receptor-delta genotype influences metabolic phenotype and may influence lipid response to statin therapy in humans: a genetics of diabetes audit and research Tayside study.
abstract: BACKGROUND
  Previous studies have identified a single-nucleotide polymorphism in the gene encoding peroxisome proliferator-activated receptor-delta (PPARD), rs2016520, that is associated with changes in metabolic disease in some but not all studies, which suggests that PPARD agonists may have therapeutic benefits for the treatment of metabolic disorders, including dyslipidemia, type 2 diabetes, and obesity.
  
  
  OBJECTIVE
  The objective of the study was to determine whether rs2016520 or other single-nucleotide polymorphism in the PPARD locus influenced the risk of developing various characteristics of metabolic disease.
  
  
  METHODS
  Haplotype tagging analysis across PPARD was performed in 11,074 individuals from the Welcome Trust U.K. Type 2 Diabetes Case Control Collection.
  
  
  RESULTS
  In subjects with and without type 2 diabetes, rs2016520 was associated with body mass index, high-density lipoprotein cholesterol, leptin, and TNFalpha and was dependent on gender.
  
  
  CONCLUSIONS
  The current results suggest differential effects of PPARdelta in males and females.
authors.affiliation: Biomedical Research Institute, Ninewells Hospital and Medical School, University of Dundee, Angus, Dundee, United Kingdom DD1 9SY. nuclear-receptor@dundee.ac.uk
authors.forename: Lindsay R
authors.initials: LR
authors.lastname: Burch
authors.forename: Louise A
authors.initials: LA
authors.lastname: Donnelly
authors.forename: Alex S F
authors.initials: AS
authors.lastname: Doney
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Brady
authors.forename: Anna M
authors.initials: AM
authors.lastname: Tommasi
authors.forename: Adrian L
authors.initials: AL
authors.lastname: Whitley
authors.forename: Catharine
authors.initials: C
authors.lastname: Goddard
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Morris
authors.forename: Michael K
authors.initials: MK
authors.lastname: Hansen
authors.forename: Colin N A
authors.initials: CN
authors.lastname: Palmer
mesh_terms: D052242:Adiponectin / Q000097:blood; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000235:genetics* / Q000378:metabolism; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000235:genetics*; D020738:Leptin / Q000097:blood; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D047494:PPAR delta / Q000235:genetics* / Q000378:metabolism*; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012727:Sex Characteristics; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D055815:Young Adult
chemical_list: D052242:Adiponectin; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D020738:Leptin; D008055:Lipids; D047494:PPAR delta; D014409:Tumor Necrosis Factor-alpha; D002784:Cholesterol